Medicure Gains 3.51% to $3.83 and Double Digits Coming Soon

Medicure (TSXV: MPH) gained by 3.51% on Friday to $3.83 per share!

MPH rose to $10.67 per share one decade ago in 2016 and averaged a price of $7.86 per share over the following 24-month time period back when it had 15.88 million shares outstanding.

Today, MPH has only 10.436 million shares outstanding and a market cap of US$27.86 million.

MPH will earn a Priority Review Voucher after it receives FDA Approval for MC-1 that it will sell to a major pharmaceutical company for an estimated US$205 million.

MPH will break out past $10.67 per share with ease in the upcoming weeks and surpass $20 per share long before the Phase 3 trial results are released in September 2027.

MC-1 really works to cure PNPO deficiency. When we say ask the most advanced AI models like Claude about it, we are being sarcastic, but still, it is okay to use them as part of your research. Anthropic (ANT) investors who buy today near the top will lose all their money as Medicure (TSXV: MPH) investors make massive profits. MPH will be $30 per share by this time next year.

Be sure you tell all of your friends and family members about Medicure during the Thanksgiving and Christmas holidays. In January we should begin to actively spread word about Medicure to biotech investors on social media. Because it is listed on the TSX Venture Exchange, no biotech investors know that Medicure even exists. U.S. listed biotech stocks in Phase 3 trials typically start at a US$100 million market cap in a worst-case scenario and those companies are always burning massive amounts of cash and don’t have Rare Pediatric Disease Designations that will earn them a Priority Review Voucher.

The FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program is authorized through September 30, 2029, so Medicure will be earning it well before the cutoff date. The PRV doesn’t expire so there will be countless major pharmaceutical companies eager to buy the PRV from Medicure for an estimated US$205 million.

Medicure MPH stock chart

Past performance is not indicative of future results. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA’s President has purchased 87,000 shares of MPH and intends to buy more shares. This communication is for informational and educational purposes only.